Tucatinib Approved for HER2-Positive Colorectal Cancer

<!DOCTYPE html> <html lang="en" dir="ltr" prefix="og: https://ogp.me/ns#"> <head> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <meta charset="utf-8" /> <script>window.CDEConfig = { "exitDisclaimerHref":{ "en":"\/policies\/linking", "es":"\/espanol\/politicas\/enlaces" }, "showFloatingDelighters":true, "environmentConfig":{ }, "glossaryConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/glossary\/v1\/" }, "drugDictionaryConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/drugdictionary\/v1\/" }, "ctsConfig":{ "apiServer":"https:\/\/clinicaltrialsapi.cancer.gov\/api\/v2", "printApiBase":"https:\/\/www.cancer.gov\/CTS.Print", "zipConversionEndpoint":"\/cts_api\/zip_code_lookup" }, "r4rConfig":{ "apiServer":"https:\/\/webapis.cancer.gov\/r4r\/v1" }, "general":{ "apiServer":"https:\/\/webapis.cancer.gov", "mediaServer":"https:\/\/nci-media.cancer.gov" }, "sitewideSearchConfig":{ "bestBetsApiServer":"https:\/\/webapis.cancer.gov\/bestbets\/v1\/", "searchApiServer":"https:\/\/webapis.cancer.gov\/sitewidesearch\/v1\/" }, "chartData": { "factBook": { "baseUrl": "\/about-nci\/budget\/fact-book", "dataType": "json" } } };</script> <script id="ncids-nav-info">window.ncidsNavInfo = { nav: { id: "860258", menu_type: "section-nav"}, item_id: 860258};</script> <meta name="description" content="FDA has approved tucatinib (Tukysa) with trastuzumab (Herceptin) for people with HER2-positive advanced colorectal cancer." /> <link rel="canonical" href="https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer" /> <meta http-equiv="content-language" content="en" /> <meta name="robots" content="index" /> <meta property="og:type" content="Website" /> <meta property="og:url" content="https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer" /> <meta property="og:title" content="Tucatinib Approved for HER2-Positive Colorectal Cancer" /> <meta property="og:description" content="FDA has approved tucatinib (Tukysa) with trastuzumab (Herceptin) for people with HER2-positive advanced colorectal cancer." /> <meta property="og:image" content="https://www.cancer.gov/sites/g/files/xnrzdm211/files/styles/cgov_social_media/public/cgov_image/media_image/2023-02/OCC-Cancer-Currents-HER2-Overexpression.jpg" /> <meta name="cgdp.domain" content="cgov" /> <meta name="cgdp.template" content="default" /> <meta name="dcterms.subject" content="News and Events" /> <meta name="dcterms.type" content="cgvBlogPost" /> <meta name="dcterms.coverage" content="nciglobal,ncienterprise" /> <meta name="dcterms.isPartOf" content="CancerCurrents" /> <meta name="dcterms.isReferencedBy" content="event1,event53" /> <meta name="dcterms.issued" content="02/10/2023 - 07:00" /> <meta name="twitter:card" content="summary" /> <link rel="icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.ico" sizes="32x32"/> <link rel="icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/favicon.svg" type="image/svg+xml"/> <link rel="apple-touch-icon" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/apple-touch-icon.png"/> <link rel="manifest" href="https://www.cancer.gov/profiles/custom/cgov_site/themes/custom/cgov/static/images/design-elements/icons/favicons/site.webmanifest"/> <meta name="x-no-op" content="none" /> <meta name="Generator" content="Drupal 10 (https://www.drupal.org)" /> <meta name="MobileOptimized" content="width" /> <meta name="HandheldFriendly" content="true" /> <meta name="viewport" content="width=device-width, user-scalable=yes, initial-scale=1, minimum-scale=1" /> <script id="cgov-adobe-url" type="text/javascript" src="//assets.adobedtm.com/6a4249cd0a2c/949e98979342/launch-5f2a5357bf66.min.js" async="async"></script> <script type="application/ld+json">{ "@context": "https://schema.org", "@graph": [ { "@type": "WebSite", "name": "National Cancer Institute (.gov)", "url": "https://www.cancer.gov" } ] }</script> <link rel="alternate" hreflang="en" href="https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer" /> <link rel="alternate" hreflang="es" href="https://www.cancer.gov/espanol/noticias/temas-y-relatos-blog/2023/fda-tucatinib-her2-cancer-colorectal" /> <title>Tucatinib Approved for HER2-Positive Colorectal Cancer - NCI</title> <link rel="preconnect" href="https://static.cancer.gov" /> <link rel="preconnect" href="https://fonts.googleapis.com"> <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin> <link href="https://fonts.googleapis.com/css2?family=Open+Sans:ital,wght@0,300;0,400;0,600;0,700;1,300;1,400;1,600;1,700&family=Poppins:ital,wght@0,300;0,400;0,500;0,600;1,300;1,400;1,500;1,600&family=Roboto+Mono:ital,wght@0,300;0,400;0,700;1,300;1,400;1,700&display=swap" rel="stylesheet"> <meta name="apple-mobile-web-app-title" content="Cancer.gov" /> <meta name="application-name" content="Cancer.gov" /> <link rel="stylesheet" media="all" href="/sites/g/files/xnrzdm211/files/css/css_dpKR6GJ0SAlxAov6RWJNbTUa0NBSCaYTn6_G1M5wkqA.css?delta=0&language=en&theme=ncids_trans&include=eJwFwUEKwCAMBMAPCXmSJLqUQI3F3Yu_7wwvhWXhREMpdTtWYNrwT7mr1cjJruNFi3c__AH3vRO8" /> <link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/ncids-common.css?smm34w" /> <link rel="stylesheet" media="all" href="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/css/blogs.css?smm34w" /> </head> <body class="has-translated-content"> <a href="#main-content" class="usa-skipnav"> Skip to main content </a> <div class="dialog-off-canvas-main-canvas" data-off-canvas-main-canvas> <section id="usa-banner" class="usa-banner" aria-label="Official government website"> <header class="usa-banner__header"> <div class="usa-banner__inner"> <div class="usa-banner__header-text"> An official website of the United States government </div> <a href="/espanol/noticias/temas-y-relatos-blog/2023/fda-tucatinib-her2-cancer-colorectal" id="lang-toggle" class="usa-button usa-button--nci-small" hreflang="es">Español</a> </div> </header> </section> <header id="nci-header" class="nci-header nci-header--megamenu" data-base-path="/"> <div class="nci-header__navbar"> <div class="nci-logo" id="extended-mega-logo"> <a href="/" aria-label="National Cancer Institute Home Page"> <picture><source media="(min-width: 1024px)" srcset="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI.svg" /> <img src="/sites/g/files/xnrzdm211/files/ncids_header/logos/Logo_NCI_Mobile.svg" alt="" /> </picture> </a> </div> <div class="nci-header-nav__secondary"> <button class="usa-button nci-header-mobilenav__open-btn">Menu</button> <form class="nci-header-search" method="get" action="/search/results" role="search"> <label class="usa-sr-only" for="nci-header-search__field"> Search </label> <input class="usa-input" id="nci-header-search__field" type="search" name="swKeyword" data-autosuggest-collection="cgov"/> <button class="usa-button nci-header-search__search-button" type="submit" aria-label="Search"> <span class="nci-header-search__label" aria-hidden="true">Search</span> <svg class="usa-icon" xmlns="http://www.w3.org/2000/svg" role="img" viewbox="0 0 24 24" aria-hidden="true"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M15.5 14h-.79l-.28-.27C15.41 12.59 16 11.11 16 9.5 16 5.91 13.09 3 9.5 3S3 5.91 3 9.5 5.91 16 9.5 16c1.61 0 3.09-.59 4.23-1.57l.27.28v.79l5 4.99L20.49 19l-4.99-5zm-6 0C7.01 14 5 11.99 5 9.5S7.01 5 9.5 5 14 7.01 14 9.5 11.99 14 9.5 14z"/> </svg> </button> </form> </div> </div> <nav aria-label="Primary navigation" class="nci-header-nav"> <div class="nci-header-nav__inner"> <ul class="nci-header-nav__primary"> <li class="nci-header-nav__primary-item"> <a href="/about-cancer" class="nci-header-nav__primary-link" data-menu-id="829"> <span>About Cancer</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/types" class="nci-header-nav__primary-link" data-menu-id="11868"> <span>Cancer Types</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/research" class="nci-header-nav__primary-link" data-menu-id="12732"> <span>Research</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/grants-training" class="nci-header-nav__primary-link" data-menu-id="914792"> <span>Grants & Training</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/news-events" class="nci-header-nav__primary-link usa-current" data-menu-id="12664"> <span>News & Events</span> </a> </li> <li class="nci-header-nav__primary-item"> <a href="/about-nci" class="nci-header-nav__primary-link" data-menu-id="10952"> <span>About NCI</span> </a> </li> </ul> </div> </nav> </header> <div class="grid-container"> <div class="grid-row flex-no-wrap"> <div class="grid-col-10"> <nav class="usa-breadcrumb usa-breadcrumb--wrap" aria-label="Breadcrumbs"> <ol class="usa-breadcrumb__list"> <li class="usa-breadcrumb__list-item"> <a href="/" class="usa-breadcrumb__link"> <span>Home</span> </a> </li> <li class="usa-breadcrumb__list-item"> <a href="/news-events" class="usa-breadcrumb__link"> <span>News & Events</span> </a> </li> <li class="usa-breadcrumb__list-item"> <a href="/news-events/cancer-currents-blog" class="usa-breadcrumb__link"> <span>Cancer Currents Blog</span> </a> </li> <li class="usa-breadcrumb__list-item usa-current" aria-current="page"> <span>Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer</span> </li> </ol> </nav> </div> <section class="cgdp-page-options cgdp-page-options--top" aria-label="Page options top"> <button class="usa-button usa-button--unstyled" onclick="window.print()"> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/> </svg> <span class="usa-sr-only"> Print </span> </button> <a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/> </svg> <span class="usa-sr-only"> Email </span> </a> </section> </div> </div> <div id="page" class="grid-container"> <div class="grid-row grid-gap"> <div data-drupal-messages-fallback class="hidden"></div> <div class="cgdpl desktop:grid-col-9"> <main id="main-content" class="contentzone"> <div>  <article> <div class="resize-content"> <h1> Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer </h1> <div id="nvcgSubTitle"> <div class="subscribeRSS"> <a class="blogRSS" href="https://public.govdelivery.com/accounts/USNIHNCI/subscriber/new?topic_id=USNIHNCI_38"><span>Subscribe</span></a> </div> </div> <div id="cgvBody" class="cgvblogpost"> <p class="blog-post-publishing-info"> <time datetime="2023-02-10T12:00:00Z">February 10, 2023</time>, by Sharon Reynolds </p> <div data-entity-embed-display="view_mode:media.image_display_article_medium" class="embedded-entity align-right"> <figure class="image-medium centered-set"> <div class="centered-element"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_article/public/cgov_image/media_image/2023-02/OCC-Cancer-Currents-HER2-Overexpression.jpg?h=1e6eb8d0&itok=UGGAOwCl" width="640" height="480" alt="An illustration showing two cancer cells side by side with different amounts of HER2 on its surface." /> </div> <figcaption> <div class="caption-container no-resize"> <p>Tucatinib (Tukysa) and trastuzumab (Herceptin) are now approved by FDA to treat some people with colorectal cancer whose tumors produce an excess of HER2 proteins. The drugs block the activity of HER2 proteins but in different ways.</p> <div class="image-photo-credit">Credit: National Cancer Institute</div> </div> </figcaption> </figure> </div> <p>Some people with colorectal cancer that can’t be removed surgically or has spread elsewhere in the body have a new treatment option. On January 19, the Food and Drug Administration (FDA) granted <a class="definition" data-glossary-id="CDR0000799144" href="/Common/PopUps/popDefinition.aspx?id=CDR0000799144&version=Patient&language=en">accelerated approval</a> to the combination of two targeted drugs, <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="3f4ac3ab-1576-4271-9a06-345bbc2adba2" href="/about-cancer/treatment/drugs/tucatinib">tucatinib (Tukysa)</a> and <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="ee9986c3-3aca-41a0-aaca-4de0002894c1" href="/about-cancer/treatment/drugs/trastuzumab">trastuzumab (Herceptin)</a> for people with advanced colorectal cancer that produces an excess amount of a <a class="definition" data-glossary-id="CDR0000046092" href="/Common/PopUps/popDefinition.aspx?id=CDR0000046092&version=Patient&language=en">protein</a> called <a class="definition" data-glossary-id="CDR0000793177" href="/Common/PopUps/popDefinition.aspx?id=CDR0000793177&version=Patient&language=en">HER2</a>.</p> <p>To be eligible to receive the new combination, people’s tumors must also not have changes in a group of genes called <em>RAS</em>, and people must have previously received at least two <a class="definition" data-glossary-id="CDR0000044930" href="/Common/PopUps/popDefinition.aspx?id=CDR0000044930&version=Patient&language=en">standard treatments</a>, including chemotherapy.</p> <p>In the clinical trial that led to the accelerated approval, called MOUNTAINEER, <a href="https://www.annalsofoncology.org/article/S0923-7534(22)01130-9/fulltext">38% of people who received the drug combination had their tumors shrink or disappear</a>. In another 33%, tumors stopped growing for some time. At the time the study results were presented last July, more than half the participants who received the drugs were still alive 2 years after beginning treatment.</p> <p>The available treatment options for people whose metastatic colorectal cancer has returned or started growing again after receiving standard treatments are not very effective, explained John Strickler, M.D., of Duke University, who led the trial. </p> <p>“That [approach] has a <a class="definition" data-glossary-id="CDR0000043983" href="/Common/PopUps/popDefinition.aspx?id=CDR0000043983&version=Patient&language=en">response rate</a> of less than 5%, and generally controls disease for around 2 to 4 months,” Dr. Strickler said. “So this treatment represents a fairly substantial breakthrough for patients who have HER2-positive disease” that has returned or started growing again.</p> <p>HER2-positive tumors make up a small minority of colorectal cancers: only about 3% overall. Focusing on smaller and smaller groups of patients with targeted therapies can make recruiting enough people to run clinical trials challenging, said Carmen Allegra, M.D., who works with NCI’s <a href="https://ctep.cancer.gov/">Cancer Therapy Evaluation Program</a> and was not involved with the study.</p> <p>“But when you do find something that helps small subsets of patients, the results are often quite impressive like this,” Dr. Allegra said</p> <h2>Cutting off fuel for cancer cells</h2> <p>HER2 plays a role in normal cell growth. In many cancer types, tumor cells make extra copies of the gene that produces the HER2 protein, known as <a class="definition" data-glossary-id="CDR0000650175" href="/Common/PopUps/popDefinition.aspx?id=CDR0000650175&version=Patient&language=en">gene amplification</a>.</p> <p>The resulting flood of HER2 protein causes cancer cells to grow uncontrollably. But, on the flip side, cancer cells may also become dependent on this extra HER2 and cutting off the flow of the protein can cause them to stop growing or die.</p> <p>HER2's role is best understood in breast cancer, where up to 30% of tumors <a class="definition" data-glossary-id="CDR0000045812" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045812&version=Patient&language=en">overexpress</a> HER2 and HER2-targeted treatments are commonly used. In the last few years, researchers have discovered that HER2 is also overproduced in some stomach and esophageal cancers, Dr. Strickler said, and researchers are teasing out its contribution to other cancer types.</p> <div data-embed-button="cgov_featured_content_button" data-entity-embed-display="view_mode:node.embedded_feature_card" data-entity-type="node" data-entity-uuid="aedf1ad2-145b-4d5f-a4b2-6f0ca4a89ac4" data-langcode="en" data-entity-embed-display-settings="[]" class="embedded-entity align-right"> <div class="feature-card"> <a href="/news-events/cancer-currents-blog/2020/tucatinib-trastuzumab-deruxtecan-her2-positive-metastatic-breast-cancer"> <div class="image-hover"> <img loading="lazy" src="/sites/g/files/xnrzdm211/files/styles/cgov_featured/public/cgov_image/media_image/2020-01/Fluorescence-in-situ-hybridization.jpg?h=3c898c73&itok=hT3JwgZT" width="425" height="319" alt="An image of breast cancer cells with strong HER2 amplification."> </div> <h3>New Treatments for Metastatic HER2+ Breast Cancer</h3> <p>Tucatinib and trastuzumab deruxtecan can benefit women who received previous HER2 treatments.</p> </a> </div> </div> <p>More and more, people with newly diagnosed metastatic colorectal cancer undergo certain types of gene sequencing, explained Dr. Strickler. This sequencing looks for gene changes that can be targeted with approved drugs, as well as mutations that can predict resistance to certain treatments.</p> <p>“Increasingly, when we were sequencing tumors to look for mutations, we were incidentally finding HER2 amplification. But we had no FDA-approved therapies targeting HER2” for colorectal cancer, Dr. Strickler said.</p> <p>He and his colleagues began a small study of two drugs targeting HER2: trastuzumab, which has been the backbone of treatment for HER2-postive breast cancer, and tucatinib, a newer drug which has proven to be particularly effective in combination with trastuzumab in breast cancer.</p> <p>In studies in mice, “it had been shown repeatedly that these drugs work better when given together,” Dr. Strickler said. “Each drug by itself has modest antitumor effects in colorectal cancer, but when you give them together, the effect is what I’d call one plus one equals three.”</p> <p>The team saw something similar in study participants. When they gave them only tucatinib, some people’s tumors stopped growing for a while but none shrank, and they ended up having trastuzumab added to their treatment, he explained.</p> <h2>Long-lasting tumor control for some people</h2> <p>Seagen Inc., which manufactures tucatinib, funded the team to conduct the larger MOUNTAINEER trial, which tested the combination of tucatinib and trastuzumab in 84 study participants whose advanced colorectal cancer had come back or hadn’t shrunk after previous treatments. Most participants had metastatic tumors in their liver and lungs. </p> <p>Participants also had to have genetic tests showing that their cancer didn’t have <em>RAS</em> mutations. Such mutations are thought to allow cancer cells to keep growing even if HER2 is blocked, rendering that treatment useless, explained Dr. Strickler.</p> <p>MOUNTAINEER participants received tucatinib and trastuzumab until their cancer started growing again, or until they experienced side effects.</p> <p>At the time the trial results were presented at the European Society for Medical Oncology World Congress on Gastrointestinal Cancers in 2022, participants’ tumors had continued to respond to the treatment for a median of just over a year. </p> <p>It will be important to keep following the remaining patients in the MOUNTAINEER trial for a while, said Dr. Allegra. “For those patients who did get a response, it lasted a long time, relatively speaking,” he said. “But whether that response rate will translate into a survival advantage over other treatments isn’t known yet.”</p> <p><a class="definition" data-glossary-id="CDR0000655248" href="/Common/PopUps/popDefinition.aspx?id=CDR0000655248&version=Patient&language=en">Median overall survival</a> in the MOUNTAINEER trial was just over 2 years. In large clinical trials, said Dr. Allegra, overall survival has been about 7 months for people with advanced colorectal cancer who have already had several treatments. However, those whose tumors overexpress HER2 and don’t have <em>RAS</em> mutations may tend to live longer regardless of what treatment they receive, he added.</p> <p>The most common side effects seen during the MOUNTAINEER trial were diarrhea, fatigue, rash, nausea, fever, and reactions to the trastuzumab infusions such as chills. The most common serious side effect was high blood pressure. Doses of tucatinib were reduced or stopped for 6% of the 84 participants due to side effects.</p> <p>However, the severity and frequency of side effects with the targeted drug combination was less than that seen with the chemotherapy drugs that would normally be used for these patients, said Dr. Strickler. </p> <h2>Combination therapies for longer responses?</h2> <p>These results of the MOUNTAINEER trial led to an ongoing follow-up study called <a href="https://clinicaltrials.gov/ct2/show/NCT05253651">MOUNTAINEER-03</a>. This <a class="definition" data-glossary-id="CDR0000045858" href="/Common/PopUps/popDefinition.aspx?id=CDR0000045858&version=Patient&language=en">randomized clinical trial</a> is testing the addition of tucatinib and trastuzumab to standard treatment regimens using chemotherapy and other targeted therapies, as initial treatment for metastatic HER2-positive colorectal cancer. </p> <p>Other trials are also testing combinations of other targeted drugs in patients with previously treated advanced colorectal cancer to see if they, like tucatinib and trastuzumab, work better when given together. </p> <p>For example, explained Dr. Allegra, another phase 3 clinical trial recently tested the combination of <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="9561052f-b0bc-43ea-89d0-8ec4256f32a7" href="/about-cancer/treatment/drugs/bevacizumab">bevacizumab (Avastin)</a> with <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="4697d798-5b17-40e5-b51b-945625b1092c" href="/about-cancer/treatment/drugs/trifluridine-tipiracilhydrochloride">trifluridine and tipiracil (Lonsurf)</a> in people with advanced colorectal cancer who had received at least two previous treatments. Those participants lived for a median of almost a year after starting treatment. Participants in that trial could receive the study drug combination regardless of the gene mutations found in their tumors.</p> <p>For people with advanced HER2-positive tumors, researchers are interested in testing other treatments that target the protein, such as <a data-entity-substitution="canonical" data-entity-type="node" data-entity-uuid="351981de-344e-448c-85fe-8d6f1b53e779" href="/about-cancer/treatment/drugs/famtrastuzumabderuxtecan-nxki">trastuzumab deruxtecan (Enhertu)</a>, which is a type of drug called an antibody<font face="Symbol"><span style="font-size: 14.6667px;">-</span></font>drug conjugate, Dr. Strickler explained.</p> <p>If these could be used after a recurrence to delay chemotherapy even further for these patients, “that could give them more options and better quality of life,” he said.</p> </div> </div> <footer class="article-footer"> <div id='cgov-blog-post-pagination' class='clearfix'> <div class='blog-post-older'> <a href="/news-events/cancer-currents-blog/2023/nci-bertagnolli-national-cancer-plan">< Older Post</a> <p><i>Doing More—Together—to End Cancer as We Know It</i></p> </div> <div class='blog-post-newer'> <a href="/news-events/cancer-currents-blog/2023/disparities-opioids-cancer-pain-end-of-life">Newer Post ></a> <p><i>Study Finds Disparities in Access to Opioids for Cancer Pain at End of Life</i></p> </div> </div> <div id="nvcgSlPublicUse"> <div class="slot-item only-SI"> <div class="public-use"> <div id="block-ncids-trans-public-use"> <p><em>If you would like to reproduce some or all of this content, see <a href="/policies/copyright-reuse">Reuse of NCI Information</a> for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Tucatinib and Trastuzumab Combination Approved for Advanced Colorectal Cancer was originally published by the National Cancer Institute.”</em></p> </div> </div> </div> </div> </footer> </article>  </div> </main> </div>   <div class="cgdpl desktop:grid-col-3"> <div id="nvcgSlListBlogRTRail" class="right-rail"> <div class="slot-item"> <div class="managed list with-date"> <h2 id="Featured+Posts">Featured Posts</h2> <ul> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/medical-cannabis-oncologists-patients-communication">Oncologists Struggle to Answer Questions About Medical Cannabis</a> <div class="byline"> <p> October 16, 2024, by Carmen Phillips </p> </div> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/mammogram-false-positives-affect-future-screening">Mammogram False Positives Can Affect Future Screening Behavior</a> <div class="byline"> <p> October 4, 2024, by Edward Winstead </p> </div> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog/2024/ancient-retrovirus-dna-ltr10-cancer">DNA From an Ancient Virus Helps Many Cancers Grow</a> <div class="byline"> <p> September 6, 2024, by Nadia Jaber </p> </div> </div> </li> </ul> </div> </div> <div class="slot-item"> <div class="managed list without-date"> <h2 id="Categories">Categories</h2> <ul> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=biology">Biology of Cancer</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=cancer-risk">Cancer Risk</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=childhood-cancer">Childhood Cancer</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=clinical-trial-results">Clinical Trial Results</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=disparities">Disparities</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=fda-approvals">FDA Approvals</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=global-health">Global Health</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=leadership-expert-views">Leadership & Expert Views</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=prevention">Prevention</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=prognosis">Prognosis</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=screening-early-detection">Screening & Early Detection</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=survivorship-supportive-care">Survivorship & Supportive Care</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=technology">Technology</a> </div> </li> <li class="general-list-item general list-item"> <div class="title-and-desc title desc container"> <a class="title" href="/news-events/cancer-currents-blog?topic=treatment">Treatment</a> </div> </li> </ul> </div> </div> <div class="slot-item"> <div class="desktop"> <div id="blog-archive-accordion"> <h2 id="archive" class="blog-archive-header"> Archive </h2> <div id="blog-archive-accordion-year"> <h3> 2024 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=11"> November </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=09"> September </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=08"> August </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=07"> July </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=06"> June </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=04"> April </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=02"> February </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2024&month=01"> January </a> (6) </li> </ul> <h3> 2023 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=11"> November </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=09"> September </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2023&month=01"> January </a> (6) </li> </ul> <h3> 2022 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=10"> October </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=09"> September </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=08"> August </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=03"> March </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2022&month=01"> January </a> (6) </li> </ul> <h3> 2021 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=11"> November </a> (4) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=10"> October </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=09"> September </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=07"> July </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=06"> June </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=05"> May </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=04"> April </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=02"> February </a> (5) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2021&month=01"> January </a> (6) </li> </ul> <h3> 2020 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=12"> December </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=10"> October </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=09"> September </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=08"> August </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=07"> July </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=06"> June </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=05"> May </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=04"> April </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=03"> March </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=02"> February </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2020&month=01"> January </a> (7) </li> </ul> <h3> 2019 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=12"> December </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=11"> November </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=10"> October </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=09"> September </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=08"> August </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=07"> July </a> (8) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=06"> June </a> (6) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=04"> April </a> (7) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=03"> March </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=02"> February </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2019&month=01"> January </a> (6) </li> </ul> <h3> 2018 </h3> <ul class="ui-helper-reset"> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=12"> December </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=11"> November </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=10"> October </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=09"> September </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=08"> August </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=07"> July </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=06"> June </a> (12) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=05"> May </a> (9) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=04"> April </a> (10) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=03"> March </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=02"> February </a> (11) </li> <li class="month"> <a href="/news-events/cancer-currents-blog?year=2018&month=01"> January </a> (10) </li> </ul> </div> </div> </div> </div> </div> </div>  </div> <section class="cgdp-page-options cgdp-page-options--bottom" aria-label="Page options bottom"> <button class="usa-button usa-button--unstyled" onclick="window.print()"> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M19 8H5c-1.66 0-3 1.34-3 3v6h4v4h12v-4h4v-6c0-1.66-1.34-3-3-3zm-3 11H8v-5h8v5zm3-7c-.55 0-1-.45-1-1s.45-1 1-1 1 .45 1 1-.45 1-1 1zm-1-9H6v4h12V3z"/> </svg> <span class="usa-sr-only"> Print </span> </button> <a class="usa-button usa-button--unstyled" href="mailto:?subject=Information from the National Cancer Institute Web Site &body=I found this information on www.cancer.gov and I'd like to share it with you: https://www.cancer.gov/news-events/cancer-currents-blog/2023/fda-tucatinib-her2-colorectal-cancer %0D%0A%0D%0A NCI's Web site, www.cancer.gov, provides accurate, up-to-date, comprehensive cancer information from the U.S. government's principal agency for cancer research. If you have questions or need additional information, we invite you to contact NCI's LiveHelp instant messaging service at https://livehelp.cancer.gov, or call the NCI's Contact Center 1-800-4-CANCER (1-800-422-6237) (toll-free from the United States)."> <svg xmlns="http://www.w3.org/2000/svg" height="24" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-hidden="true" focusable="false"> <path d="M0 0h24v24H0z" fill="none"/> <path d="M20 4H4c-1.1 0-1.99.9-1.99 2L2 18c0 1.1.9 2 2 2h16c1.1 0 2-.9 2-2V6c0-1.1-.9-2-2-2zm0 14H4V8l8 5 8-5v10zm-8-7L4 6h16l-8 5z"/> </svg> <span class="usa-sr-only"> Email </span> </a> </section> </div> <div id="block-ncidsfooterenglish"> <footer class="usa-footer usa-footer--nci-big" id="nci-footer" aria-label="Footer" > <div class="grid-container usa-footer__return-to-top"> <a href="#top" aria-label="Back To Top"><span>Back To Top</span></a> </div> <div class="usa-footer__primary-section"> <div class="grid-container"> <div class="grid-row grid-gap"> <div class="tablet:grid-col-8"> <nav class="usa-footer__nav" aria-label="Footer navigation"> <div class="grid-row grid-gap-4"> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">About</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/about-website">About This Website</a> </li> <li class="usa-footer__secondary-link"> <a href="/espanol">en Español</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/copyright-reuse">Reuse & Copyright</a> </li> <li class="usa-footer__secondary-link"> <a href="/social-media">Social Media</a> </li> </ul> </section> </div> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">Resources</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/contact">Contact Us</a> </li> <li class="usa-footer__secondary-link"> <a href="/publications">Publications</a> </li> <li class="usa-footer__secondary-link"> <a href="/publications/dictionaries/cancer-terms" >Dictionary of Cancer Terms</a > </li> <li class="usa-footer__secondary-link"> <a href="/research/participate/clinical-trials-search" >Find a Clinical Trial</a > </li> </ul> </section> </div> <div class="mobile-lg:grid-col-6 desktop:grid-col-4"> <section class="usa-footer__primary-content usa-footer__primary-content--collapsible" > <div class="usa-footer__primary-link">Policies</div> <ul class="usa-list usa-list--unstyled"> <li class="usa-footer__secondary-link"> <a href="/policies/accessibility">Accessibility</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/foia">FOIA</a> </li> <li class="usa-footer__secondary-link"> <a href="/policies/privacy-security" >Privacy & Security</a > </li> <li class="usa-footer__secondary-link"> <a href="/policies/disclaimer">Disclaimers</a> </li> <li class="usa-footer__secondary-link"> <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" >Vulnerability Disclosure</a > </li> </ul> </section> </div> </div> </nav> </div> <div class="tablet:grid-col-4"> <div class="usa-sign-up"> <div class="usa-sign-up__heading">Sign up for email updates</div> <form action="https://public.govdelivery.com/accounts/USNIHNCI/subscribers/qualify" aria-label="Footer subscribe" class="usa-form" accept-charset="UTF-8" method="post" novalidate target="_blank" id="signup" > <input type="hidden" name="category_id" id="category_id" value="" /> <div class="usa-form-group"> <label class="usa-label" for="email"> Enter your email address </label> <input class="usa-input width-full" id="email" name="email" type="email" value="" /> </div> <button class="usa-button usa-button--accent-warm" type="submit"> Sign up </button> </form> </div> </div> </div> </div> </div> <div class="usa-footer__secondary-section"> <div class="grid-container"> <div class="grid-row grid-gap"> <div class="usa-footer__logo grid-row desktop:grid-col-5"> <div class="mobile-lg:grid-col-auto desktop:margin-bottom-3"> <p class="usa-footer__logo-heading"> <span class="logo__agency-name">National Cancer Institute </span> <span class="logo__parent-organization" >at the National Institutes of Health</span > </p> </div> </div> <div class="usa-footer__contact-links mobile-lg:grid-col-7"> <div class="usa-footer__contact-heading">Contact Us</div> <div class="usa-footer__address"> <div class="usa-footer__contact-info grid-row grid-gap"> <div class="tablet:grid-col-auto"> <a href="https://livehelp.cancer.gov/">Live Chat</a> </div> <div class="tablet:grid-col-auto"> <a href="tel:1-800-4-CANCER">1-800-4-CANCER</a> </div> <div class="tablet:grid-col-auto"> <a href="mailto:NCIinfo@nih.gov">NCIinfo@nih.gov</a> </div> <div class="tablet:grid-col-auto"> <a class="no-exit-notification" href="https://nci.az1.qualtrics.com/jfe/form/SV_aeLLobt6ZeGVn5I" target="_blank" >Site Feedback</a > </div> </div> </div> </div> </div> <div class="grid-row grid-gap"> <div class="usa-footer__social-links desktop:grid-col-5"> <div class="usa-footer__social-heading">Follow us</div> <div class="grid-row grid-gap-1 nci-big__social"> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.facebook.com/cancer.gov" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="24" class="usa-icon" role="img" aria-labelledby="facebook-title" > <title id="facebook-title">Facebook</title> <rect fill="none" height="24" width="24" /> <path d="M22,12c0-5.52-4.48-10-10-10S2,6.48,2,12c0,4.84,3.44,8.87,8,9.8V15H8v-3h2V9.5C10,7.57,11.57,6,13.5,6H16v3h-2 c-0.55,0-1,0.45-1,1v2h3v3h-3v6.95C18.05,21.45,22,17.19,22,12z" /> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://twitter.com/thenci" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="x-title" > <title id="x-title">Follow on X</title> <path d="M12 22c5.5 0 10-4.5 10-10S17.5 2 12 2 2 6.5 2 12s4.5 10 10 10zm5.2-15.6L13.3 11l4.3 6.2h-3.1L11.6 13 8 17.2h-.9l4.1-4.8-4.1-6h3.1l2.7 3.9 3.4-3.9h.9zm-5.6 5.4.4.6 2.8 4h1.4l-3.5-5-.4-.6-2.6-3.7H8.3l3.3 4.7z" /> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.instagram.com/nationalcancerinstitute/" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="instagram-title" > <title id="instagram-title">Instagram</title> <g id="Instagram"> <path d="M12,10a2,2,0,1,0,2,2A2,2,0,0,0,12,10Z" /> <path d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm6,12.69A3.32,3.32,0,0,1,14.69,18H9.31A3.32,3.32,0,0,1,6,14.69V9.31A3.32,3.32,0,0,1,9.31,6h5.38A3.32,3.32,0,0,1,18,9.31Z" /> <path d="M16.94,9.31a2.25,2.25,0,0,0-2.25-2.25H9.31A2.25,2.25,0,0,0,7.06,9.31v5.38a2.25,2.25,0,0,0,2.25,2.25h5.38a2.25,2.25,0,0,0,2.25-2.25h0ZM12,15.09A3.09,3.09,0,1,1,15.09,12,3.09,3.09,0,0,1,12,15.09Zm3.77-5.75a.79.79,0,0,1-.55.23.83.83,0,0,1-.55-.23.78.78,0,0,1,0-1.11A.82.82,0,0,1,15.22,8a.78.78,0,0,1,.55,1.33Z" /> </g> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.youtube.com/NCIgov" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="youtube-title" > <title id="youtube-title">Youtube</title> <g id="YouTube"> <path d="M12,2A10,10,0,1,0,22,12,10,10,0,0,0,12,2Zm5.75,12.91A1.49,1.49,0,0,1,16.69,16a34.65,34.65,0,0,1-4.69.26A34.65,34.65,0,0,1,7.31,16a1.49,1.49,0,0,1-1.06-1.06A15.88,15.88,0,0,1,6,12a15.88,15.88,0,0,1,.25-2.91A1.49,1.49,0,0,1,7.31,8,34.65,34.65,0,0,1,12,7.77,34.65,34.65,0,0,1,16.69,8a1.49,1.49,0,0,1,1.06,1.06A15.88,15.88,0,0,1,18,12,15.88,15.88,0,0,1,17.75,14.91Z" /> <polygon points="10.77 13.78 13.91 12 10.77 10.22 10.77 13.78" /> </g> </svg> </a> </div> <div class="grid-col-auto"> <a class="usa-social-link no-exit-notification" href="https://www.linkedin.com/company/nationalcancerinstitute/" > <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" class="usa-icon" role="img" aria-labelledby="linkedin-title" > <title id="linkedin-title">Linkedin</title> <g id="final"> <path d="M12,2C6.48,2,2,6.48,2,12s4.48,10,10,10s10-4.48,10-10S17.52,2,12,2z M8.912001,17.584H6.584v-7.472h2.328001V17.584z M7.744,9.104C6.992,9.104,6.4,8.488,6.4,7.76c0-0.752,0.592-1.344,1.344-1.344c0.728,0,1.343999,0.592,1.343999,1.344 C9.087999,8.488,8.472,9.104,7.744,9.104z M17.6,17.584h-2.328v-3.64c0-0.856-0.024001-1.967999-1.216001-1.967999 s-1.392,0.927999-1.392,1.912v3.696H10.36v-7.472h2.224v1.008h0.024c0.464-0.752,1.296-1.216001,2.199999-1.192 c2.352001,0,2.792,1.552001,2.792,3.544001C17.6,13.472,17.6,17.584,17.6,17.584z" /> </g> </svg> </a> </div> </div> </div> <div class="usa-footer__contact-links desktop:grid-col-7"> <div class="usa-footer__address height-full"> <div class="usa-footer__contact-info grid-row grid-gap height-full"> <address> <a href="https://www.hhs.gov/" >U.S. Department of Health and Human Services </a> <a href="https://www.nih.gov/" >National Institutes of Health </a> <a href="https://www.cancer.gov/">National Cancer Institute </a> <a href="https://usa.gov/">USA.gov</a> </address> </div> </div> </div> </div> </div> </div> </footer> </div> </div> <script src="/sites/g/files/xnrzdm211/files/js/js_qW3TLjdEty3QtOepUCSY4uh6BQEGkRIL3qUMnp3WXG4.js?scope=footer&delta=0&language=en&theme=ncids_trans&include=eJwFwUEKwCAMBMAPCXmSJLqUQI3F3Yu_7wwvhWXhREMpdTtWYNrwT7mr1cjJruNFi3c__AH3vRO8"></script> <script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/ncids-common.js?smm34w"></script> <script src="/profiles/custom/cgov_site/themes/custom/ncids_trans/dist/js/blogs.js?smm34w"></script> </body> </html>

CINXE.COM

Tucatinib Approved for HER2-Positive Colorectal Cancer - NCI